. "Appendix D-11: The Prospects for Immunizing Against Rabies Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
From among these various vaccine strategies the committee chose to evaluate three candidates that it felt were technically feasible within a decade and were representative of fundamentally different strategies. The three candidates selected were a vero cell derived vaccine, a glycoprotein based vaccine, and a vector vaccine approach.
Acha, P.N. 1981. A review of rabies prevention and control in the Americas, 1970–1980. Overall status of rabies. Bull. Off. Int. Epiz. 93(1–2):9–52.
American Public Health Association. 1985. Rabies. Pp. 310–318 in Control of Communicable Diseases in Man, A.S.Benenson, ed. Washington, D.C.: American Public Health Association.
Barth, R., H.Gruschkau, U.Bijok, J.Hilfenhaus, J.Hinz, L.Mikke, H.Moser, O.Jaeger, H.Ronneberger, and E.Weinmann. 1984. A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PECE-vaccine by laboratory tests. J. Biol. Stand. 12:29–46.
Keller, H., A.Gluck, A.Wegmann, and A.I.Wandeler. 1984. Immunogenicity of a new, highly purified and concentrated duck embryo rabies vaccine. Schweiz. Med. Wschr. 114:648–653.
Koprowski, H., K.J.Reagan, R.I.McFarlan, B.Dietzschold, and T.J. Wiktor. 1985. New generation of rabies vaccines: Rabies glycoprotein gene recombinants, anti-idiotypic antibodies and synthetic peptides. Pp. 151–156 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A.Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.
Lathe, R., M.-P.Kieny, J.-P.Lecocq, P.Drillien, T.J.Wiktor, and H. Koprowski. 1985. Immunization against rabies using a vaccinia-rabies recombinant virus expressing surface glycoprotein. Pp. 157–162 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A. Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.
Malek, L.T., G.Soostmeyer, R.T.Garvin, and E.James. 1984. The rabies glycoprotein gene is expressed in Escherichia coli as a denatured polypeptide. Pp. 203–208 in Modern Approaches to Vaccines, R.M.Chanock and R.A.Lerner, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.
Population Reference Bureau. 1984. 1984 World Population Data Sheet. Washington, D.C.: Population Reference Bureau.
Rubin, R.H., J.Black, and G.R.Sharpless. 1969. Rabies in citizens of the United States. 1963–1968: Epidemiology, treatment, and complications of treatment. J. Infect. Dis. 120:268–273.
Schneider, L.G., and K.Bögel. 1983. The current global situation of human and canine rabies and its control. Paper presented at the Third Inter-American Meeting, at the Ministerial Level, on Animal Health, Washington, D.C., April 11–14, 1983.